This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. In a previous post I was extolling the virtues of leading a private company. Specifically, the freedom of being able

Venture-backed biotechs continue their blistering pace of funding. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $2.1B was invested in biotech companies in 2Q 2015, bringing the year

This blog was written by Bill Marshall, co-founder and CEO of miRagen Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. microRNAs are an exciting new class of gene regulatory molecules that act on systems biology, and their modulation

The stock market has been a wild ride of late – big moves up and down, NYSE getting halted, Grexit, China – lots of reasons for added skittishness. The VIX index, which measures the volatility of the S&P500, has gone

External models of R&D innovation are the rage in Pharma today, as they should be – the future of our industry depends on a great deal more rather than less collaboration. In a very healthy way, lots of experiments are

Figuring out what disease areas are attracting the most venture funding and deal-related capital in startup and emerging biotech has historically been quite challenging as few if any datasets track it comprehensively. But late last week, on the eve of

This blog was written by Jeff Hatfield, CEO of Pennsylvania-based Vitae Pharmaceuticals, as part of the “From the Trenches” feature of LifeSciVC. Next week, BIO returns to Philadelphia for its massive annual convention, bringing together from around the world more than

This blog was written by Ankit Mahadevia, co-founder of Spero, Synlogic, and Rodin Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. The concept of “getting s#it done” is central to our lives as entrepreneurs. With time and capital

With the start of the American Society of Clinical Oncology meeting, all eyes in the biopharma investor community are on Chicago. Social media is alive with #ASCO15 tweets and companies big and small are firing out press releases. Signal from

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. Early this week, Intercept Pharmaceuticals announced the much awaited design of their Ph. 3 clinical trial of Obeticholic Acid (OCA)

This blog was written by Kevin Pojasek, co-founder and Acting CEO of Quartet Medicine and Atlas EIR, as part of the “From the Trenches” feature of LifeSciVC. “Most of the smartest people work somewhere else.” The famous Bill Joy quote, often

Amidst lofty public markets and robust fund flows, it’s easy to forget the importance of equity capital efficiency in building new biotech companies. But like gravity, it’s a fundamental principle and rests at the heart of generating quality returns in